Lysine-Proline-Valine (KPV) is a tripeptide fragment corresponding to residues 11-13 of the full-length α-melanocyte-stimulating hormone (α-MSH). α-MSH is a 13-amino acid neuropeptide derived from proopiomelanocortin (POMC) and is involved in various physiological processes including pigmentation, energy homeostasis, and inflammation. The KPV fragment was identified through research investigating the functional domains of α-MSH, revealing that this small terminal segment retains significant biological activity, particularly in modulating inflammatory responses, despite lacking the classic melanotropic (pigmentation-inducing) activity of the full peptide. Its significance lies in its role as a minimal, potent anti-inflammatory peptide derived from a larger endogenous hormone, offering a simplified structure for studying melanocortin receptor signaling and therapeutic applications.
Quick Facts
| Also Known As | KPV, α-MSH 11-13 fragment, Melanocortin peptide fragment |
|---|---|
| Sequence | Lys-Pro-Val |
| Molecular Formula | Unknown |
| Molecular Weight | Unknown |
Research Parameters
| Half-Life | Unknown |
|---|---|
| Stability | Unknown. For research peptides, lyophilized powder is typically stable for extended periods when stored correctly. Stability after reconstitution in aqueous solvents is likely limited and should be determined experimentally. |
| Solubility | Recommended reconstitution solvent in research is typically sterile water or bacteriostatic water for injection. |
| Storage (Lyophilized) | For research purposes, lyophilized powder should be stored at -20°C or lower, protected from light and moisture. |
| Storage (Reconstituted) | After reconstitution, research solutions should be stored at 2-8°C (refrigerated) and used within a short timeframe, often suggested within 24-48 hours if stability data is unavailable. |
| Typical Research Dose | 10-100 mcg/kg |
| Cycle Parameters | Research protocols typically involve daily administration via subcutaneous or intraperitoneal injection for short-term periods, such as 5-7 days, coinciding with an induced inflammatory model. No standard 'cycle' with off-periods is defined in preclinical research. |
| Amino Acid Count | 3 |
Mechanism of Action
KPV exerts its primary effects through modulation of inflammatory pathways, acting as a fragment of α-MSH which typically binds to melanocortin receptors (MCRs), particularly MC1R. However, KPV's small size suggests it may interact with these receptors differently or influence downstream signaling cascades directly.
Anti-inflammatory Pathway: KPV inhibits the production and release of pro-inflammatory cytokines and mediators. It has been shown to reduce the expression of key inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) in various experimental models.
NF-κB Inhibition: Research indicates that KPV can suppress the activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway, a central transcriptional regulator of inflammation. This inhibition reduces the expression of genes involved in the inflammatory response.
Cytoprotective Effects: Beyond anti-inflammatory action, KPV exhibits cytoprotective properties, potentially helping to protect cells from inflammatory damage and apoptosis in stressed environments, though the precise mechanisms for this protection are still under investigation.
Research Applications
Inflammation Research: KPV has been extensively studied in models of inflammatory diseases. It demonstrates potent anti-inflammatory effects in experimental setups involving colitis, peritonitis, and skin inflammation. Its ability to modulate cytokine production makes it a valuable tool for understanding the role of melanocortin peptides in immune regulation.
Dermatological Research: Given its origin from α-MSH, KPV is investigated in dermatological contexts, particularly for inflammatory skin conditions. Studies explore its potential to mitigate inflammation in models of contact dermatitis or other immune-mediated skin disorders without inducing pigmentary changes.
Gastrointestinal Research: In models of intestinal inflammation, such as experimental colitis, KPV has shown efficacy in reducing inflammatory parameters and improving mucosal integrity. This makes it a candidate peptide for studying novel therapeutic approaches for inflammatory bowel diseases.
Safety & Side Effects
The safety profile of KPV is primarily defined by animal studies. In these preclinical models, it has generally been reported to be well-tolerated at the research doses used, with no significant adverse effects commonly noted. Given its anti-inflammatory nature, theoretical concerns might include potential immunosuppression at high doses, but this has not been robustly documented. There are no widely reported anecdotal side effects from research use, as human data is absent. Its derivation from an endogenous peptide suggests a potentially favorable safety profile, but comprehensive toxicology studies are lacking.
Dosage Information
All information presented is derived from preclinical research studies only and does not constitute human dosing guidelines.
In animal research studies, typical doses range from approximately 10 to 100 micrograms per kilogram (μg/kg) administered via subcutaneous or intraperitoneal injection. Frequency of administration varies by study design, often involving daily injections over a period ranging from several days to a week during acute inflammatory challenge models. Duration of treatment in published protocols is typically short-term, aligned with the experimental inflammatory episode.
References
Getting, S.J., et al. 'The melanocortin peptide KPV attenuates the inflammatory response in experimental peritonitis.' Inflammation Research, 2006.
Kokkola, R., et al. 'Anti-inflammatory effects of the α-MSH fragment KPV in a murine model of colitis.' Journal of Pharmacology and Experimental Therapeutics, 2005.
Brzoska, T., et al. 'α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.' Expert Opinion on Biological Therapy, 2008.
Taylor, A.W., et al. 'The neuropeptide α-MSH in autoimmunity and inflammation.' Journal of Neuroimmunology, 2006.
Luger, T.A., et al. 'The role of melanocortins in skin homeostasis.' Hormone Research, 2000.
Catania, A., et al. 'The melanocortin system in control of inflammation.' The Scientific World Journal, 2010.